Manufacturer: iebpharma
Manufacturer: iebpharma
Blog Article
Ovarian Cancer: Maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Breast Cancer: Treatment of HER2-negative metastatic breast cancer with a germline BRCA mutation
Pancreatic Cancer: Treatment of metastatic pancreatic cancer with a germline BRCA mutation, previously treated with platinum-based chemotherapy
Prostate Cancer: Treatment of metastatic castration-resistant prostate cancer with germline or somatic HRR gene mutations, including BRCA1 and BRCA2
Recommended Dose: Olanib 150 mg (Olaparib) twice a day, for a total daily dose of 600 mg
Duration: Treatment should continue until disease progression or unacceptable side effects occur
Container Type: HDPE
Number of Tablets: 120 tablets per container
Tablet Strength: Each tablet contains 150 mg of Olaparib
Administration: The tablets should be taken orally with water
Timing: The recommended dosing schedule is twice a day, at approximately 12-hour intervals
Contraindications: Olanib 150 mg is contraindicated in patients with severe renal impairment or severe hepatic impairment
Warnings: Patients should be monitored for signs of myelosuppression, gastrointestinal toxicity, and other adverse reactions
Indicated for the treatment of certain types of advanced cancers, including:
Maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Treatment of HER2-negative metastatic breast cancer with a germline BRCA mutation
Treatment of metastatic pancreatic cancer with a germline BRCA mutation
Treatment of metastatic castration-resistant prostate cancer with germline or somatic HRR gene mutations
Helps inhibit the activity of PARP enzymes, which are involved in DNA repair, leading to cancer cell death
Active Ingredient: Olaparib 150 mg
Olaparib is a PARP (Poly (ADP-ribose) polymerase) inhibitor that works by blocking the activity of PARP enzymes, which are involved in DNA repair in cancer cells
This disrupts the ability of cancer cells to repair their DNA, leading to cell death
Olanib (olaparib) has the potential to interact with several other medications:
Avoid concomitant use of strong CYP3A inducers, as they can decrease olaparib plasma concentrations. Examples include:
Phenytoin
Rifampicin
Carbamazepine
St. John’s wort
Strong or moderate inhibitors of CYP3A can increase olaparib plasma concentrations. Concomitant use should be avoided or the dose of olaparib may need to be reduced.
Clinical studies indicate a potentiation and prolongation of myelosuppressive toxicity when olaparib is combined with other myelosuppressive anticancer agents, including DNA damaging agents.
Grapefruit and Seville oranges can increase the chance of side effects with olaparib and should be avoided.
Phone: +8801933042721
Email: iebpharma108@gmail.com
Sector 3, Road 8, Uttara-1230 Dhaka, Bangladesh
website: https://iebpharma.com